{"allowContribute":false,"item":{"activeCommit":"77b971b579ba2c0611928603b96d5525da5b7795","apis":{"routes":[],"types":{}},"backendSchedules":null,"bundleHash":"e419d19e0dfb125e","createdAt":1787242790156,"displayName":"藥華藥研究面板","gitCommit":"77b971b579ba2c0611928603b96d5525da5b7795","id":"83647dfda1d31d8e7369fe2d","isPublic":true,"itemType":"PLUGIN","name":"藥華藥研究面板","pluginDir":"83647dfda1d31d8e7369fe2d","repositoryID":"repo_6bc82776b16eaf1b5aa657d3","status":"active","updatedAt":1787243019684,"updatedBy":{"userId":"6a8724df01545cc8e3013a","userName":"Prean589"},"version":5},"ownerMemberId":"6a8724df01545cc8e3013a","ownerName":"Prean589","publicPlugins":{"PLUGIN":{"pluginItemId":"83647dfda1d31d8e7369fe2d","pluginDir":"83647dfda1d31d8e7369fe2d","bundleHash":"e419d19e0dfb125e","live":true}},"subtree":[{"activeCommit":"77b971b579ba2c0611928603b96d5525da5b7795","apis":{"routes":[],"types":{}},"backendSchedules":null,"bundleHash":"e419d19e0dfb125e","createdAt":1787242790156,"displayName":"藥華藥研究面板","gitCommit":"77b971b579ba2c0611928603b96d5525da5b7795","id":"83647dfda1d31d8e7369fe2d","isPublic":true,"itemType":"PLUGIN","name":"藥華藥研究面板","pluginDir":"83647dfda1d31d8e7369fe2d","repositoryID":"repo_6bc82776b16eaf1b5aa657d3","status":"active","updatedAt":1787243019684,"updatedBy":{"userId":"6a8724df01545cc8e3013a","userName":"Prean589"},"version":5},{"content":"\u003cp\u003e藥華藥 8/29 獲美國 FDA 核准 Ropeg 用於所有成人 ET 患者，為近 30 年首款 ET 新藥、首款全線 ET 藥、首款 ET 干擾素療法。美國約 17 萬患者、年藥費約 26 萬美元，美日雙全線到手後，下一階段看美國處方爬坡與 2027 EPS 上修幅度。\u003c/p\u003e","createdAt":1788518116371,"id":"bc5005a8314730f0e525adc1","itemType":"RESEARCH_INSIGHT","name":"美國 FDA 核准 Ropeg 全線 ET，創三項第一","originPluginDir":"83647dfda1d31d8e7369fe2d","originPluginID":"83647dfda1d31d8e7369fe2d","parents":{"default_holding_folder_6a8724df01545cc8e3013a":1788518116371},"symbol":"6446","updatedAt":1788518116371,"updatedBy":{"agentId":"ca789de2c6125f7ff03fa952","agentName":"個股研究員","userId":"6a8724df01545cc8e3013a","userName":"Prean589"},"version":1},{"content":"\u003cp\u003e8/31 創 1,645 元天價後殺跌停，9/4 收 1,310 元、高點回檔約 20.4%，近 5 日三大法人賣超約 3,270 張。市場論述已從賭藥證轉為看 ET 營收爬坡，另需留意武田 PV 新藥的競爭與黑框警語影響。\u003c/p\u003e","createdAt":1788518116371,"id":"f64886f9b26052240406a039","itemType":"RESEARCH_INSIGHT","name":"利多出盡高點回檔兩成，焦點轉向營收兌現","originPluginDir":"83647dfda1d31d8e7369fe2d","originPluginID":"83647dfda1d31d8e7369fe2d","parents":{"default_holding_folder_6a8724df01545cc8e3013a":1788518116571},"symbol":"6446","updatedAt":1788518116371,"updatedBy":{"agentId":"ca789de2c6125f7ff03fa952","agentName":"個股研究員","userId":"6a8724df01545cc8e3013a","userName":"Prean589"},"version":1},{"content":"\u003cp\u003e9/4 季度調整確定新增藥華藥、刪除世芯-KY，9/18 交易結束後生效。藥華藥將成 0050 唯一生技股，0050 規模約 2.35 兆，被動買盤於生效日前後進場，為流動性利多而非基本面改變。\u003c/p\u003e","createdAt":1788518116371,"id":"28cfdda338940fda4a8ef98e","itemType":"RESEARCH_INSIGHT","name":"確定納入臺灣50成分股，9/18 生效","originPluginDir":"83647dfda1d31d8e7369fe2d","originPluginID":"83647dfda1d31d8e7369fe2d","parents":{"default_holding_folder_6a8724df01545cc8e3013a":1788518116471},"symbol":"6446","updatedAt":1788518116371,"updatedBy":{"agentId":"ca789de2c6125f7ff03fa952","agentName":"個股研究員","userId":"6a8724df01545cc8e3013a","userName":"Prean589"},"version":1},{"content":"\u003cp\u003e藥華藥 08/31 獲 FDA 核准 BESREMi 全線 ET（PDUFA 08/30 達標，次日官宣，近 30 年美國首個 ET 新藥，仿單全基因型/全病程含初治）與 08/24 日本全線形成美日雙藥證，二元風險解除。\u003cb\u003e09/01 利多出貨 -9.71% 屬獲利了結，敘事切向放量執行\u003c/b\u003e：筆型注射器 7 月開賣、0050 被動資金 9/4 公告、Q2 EPS 6.13 元創新高，續列 5 檔核心之首（風險 2/5、組合錨 30–40%）。\u003c/p\u003e","createdAt":1788259681330,"id":"69e89d06ee47d644daa7c434","itemType":"RESEARCH_INSIGHT","name":"9/01 深度研究：08/31 FDA 全線 ET 核准兌現，美日雙藥證進入放量期","originPluginDir":"83647dfda1d31d8e7369fe2d","originPluginID":"83647dfda1d31d8e7369fe2d","parents":{"default_holding_folder_6a8724df01545cc8e3013a":1788259681330},"symbol":"6446","updatedAt":1788259681330,"updatedBy":{"agentId":"6cf30c848093a4ccab6df848","agentName":"深度研究員","userId":"6a8724df01545cc8e3013a","userName":"Prean589"},"version":1},{"content":"\u003cp\u003e藥華藥 08/24 獲日本厚生勞動省核准 \u003cb\u003eRopeg 全線 ET（全球首張涵蓋所有 ET 病患藥證）\u003c/b\u003e、當日 +5.36% 至 1475 元，\u003cb\u003e2 天後 08/30 美國 ET PDUFA 為 12 家最短催化\u003c/b\u003e，仿單是否比照日本全線放行為關鍵分歧。Q2 EPS 6.13 元創新高、上半年 11.35 元，前 7 月 144.84 億年增 77.46%，筆型注射器 7 月美國開賣為放量引擎；本週深度研究續列 \u003cb\u003e5 檔核心之首（風險 2/5、組合錨）\u003c/b\u003e，法人目標價 1900–2090 元。\u003c/p\u003e","createdAt":1787914132949,"id":"c46aae0b40977bcdc25a72e7","itemType":"RESEARCH_INSIGHT","name":"8/28 深度研究：日本全線 ET 已兌現、2 天後美國 PDUFA 為最短雙催化","originPluginDir":"83647dfda1d31d8e7369fe2d","originPluginID":"83647dfda1d31d8e7369fe2d","parents":{"default_holding_folder_6a8724df01545cc8e3013a":1787914132949},"symbol":"6446","updatedAt":1787914132949,"updatedBy":{"agentId":"6cf30c848093a4ccab6df848","agentName":"深度研究員","userId":"6a8724df01545cc8e3013a","userName":"Prean589"},"version":1},{"content":"\u003cp\u003e8/24 獲日本厚生勞動省核准 BESREMi 全線 ET（仿單無二線限制），為 Ropeg 全球首張一線可用藥證，8/30 美國 PDUFA 倒數 2 天為下一關鍵二元催化。\u003c/p\u003e","createdAt":1787913348898,"id":"f8f49798ba6abad15a7096a8","itemType":"RESEARCH_INSIGHT","name":"日本全線 ET 08/24 核准：Ropeg 全球首張「所有 ET 病患」藥證","originPluginDir":"83647dfda1d31d8e7369fe2d","originPluginID":"83647dfda1d31d8e7369fe2d","parents":{"default_holding_folder_6a8724df01545cc8e3013a":1787913348898},"symbol":"6446","updatedAt":1787913348898,"updatedBy":{"agentId":"ca789de2c6125f7ff03fa952","agentName":"個股研究員","userId":"6a8724df01545cc8e3013a","userName":"Prean589"},"version":1},{"content":"\u003cp\u003e以 8/24 數據計市值排名 34–37、公眾流通率 89.77% 已越門檻，市場點名 0050 唯一生技股候選，9/4 公告、9/18 生效將帶動被動資金買盤。\u003c/p\u003e","createdAt":1787913348898,"id":"2a291e0f87e4d288d6ddd570","itemType":"RESEARCH_INSIGHT","name":"0050換股倒數 9/4公告：藥華藥市值34-37名入選呼聲最高","originPluginDir":"83647dfda1d31d8e7369fe2d","originPluginID":"83647dfda1d31d8e7369fe2d","parents":{"default_holding_folder_6a8724df01545cc8e3013a":1787913348998},"symbol":"6446","updatedAt":1787913348898,"updatedBy":{"agentId":"ca789de2c6125f7ff03fa952","agentName":"個股研究員","userId":"6a8724df01545cc8e3013a","userName":"Prean589"},"version":1},{"content":"\u003cp\u003eQ2 單季 68.6 億年增 90.3% 創高、毛利率 94.2%，7 月再衝 25.07 億月增 7.48% 單月新高，筆型注射器 7 月美國開賣為下半年加速引擎。\u003c/p\u003e","createdAt":1787913348898,"id":"8a8786d2f409b3ff28726357","itemType":"RESEARCH_INSIGHT","name":"7月營收25.07億創新高、8/25法說：上半年120億年增75%","originPluginDir":"83647dfda1d31d8e7369fe2d","originPluginID":"83647dfda1d31d8e7369fe2d","parents":{"default_holding_folder_6a8724df01545cc8e3013a":1787913349098},"symbol":"6446","updatedAt":1787913348898,"updatedBy":{"agentId":"ca789de2c6125f7ff03fa952","agentName":"個股研究員","userId":"6a8724df01545cc8e3013a","userName":"Prean589"},"version":1},{"content":"\u003cp\u003e08/24 獲日本厚生勞動省核准 Ropeg 全線 ET（全球首張涵蓋所有 ET 病患），收 1475 元 +5.36%；Q2 EPS 6.13 元創新高、獲利年增 204%，前 7 月營收 144.84 億年增 77.46%。\u003cb\u003e08/30 美國 ET PDUFA\u003c/b\u003e 為最短催化，若過關將打開全線用藥天花板，法人最高目標價 2,090 元。\u003c/p\u003e","createdAt":1787654733089,"id":"de1b450853d2422d0a6a4d99","itemType":"RESEARCH_INSIGHT","name":"8/25 深度研究：日本全線 ET 已批、5 天後美國 PDUFA 決勝","originPluginDir":"83647dfda1d31d8e7369fe2d","originPluginID":"83647dfda1d31d8e7369fe2d","parents":{"default_holding_folder_6a8724df01545cc8e3013a":1787654733089},"symbol":"6446","updatedAt":1787654733089,"updatedBy":{"agentId":"6cf30c848093a4ccab6df848","agentName":"深度研究員","userId":"6a8724df01545cc8e3013a","userName":"Prean589"},"version":1},{"content":"\u003cp\u003e市值約 5,808 億元、台股排名第 37，已越過 0050「非成分股市值進前 40」納入門檻，市場點名入選機率最高。定審基準日 8/24、公告 9/4、生效 9/18，入選將帶動被動式資金買入，與 8/30 美國 ET 藥證 PDUFA 形成雙重催化。\u003c/p\u003e","createdAt":1787308493704,"id":"a24f2369692f1a31c6606caf","itemType":"RESEARCH_INSIGHT","name":"0050 成分股調整：藥華藥入選機率極高，被動資金催化","originPluginDir":"83647dfda1d31d8e7369fe2d","originPluginID":"83647dfda1d31d8e7369fe2d","parents":{"default_holding_folder_6a8724df01545cc8e3013a":1787308493704},"symbol":"6446","updatedAt":1787308493704,"updatedBy":{"agentId":"ca789de2c6125f7ff03fa952","agentName":"個股研究員","userId":"6a8724df01545cc8e3013a","userName":"Prean589"},"version":1},{"content":"\u003cp\u003e異位 PI3Kα 抑制劑 Zovegalisib 獲 FDA 突破性療法認定，ESMO TAT 雙藥 mPFS 11.1 個月、三藥 ORR 44%，後線乳癌強數據；現金 $642.1M 可燒到 2029。但一年股價漲約 5 倍、評價偏熱，追高留意回檔風險。\u003c/p\u003e","createdAt":1787245254074,"id":"2673372a125bc018753fc818","itemType":"RESEARCH_INSIGHT","name":"Relay Zovegalisib 獲突破性療法、數據亮眼但評價已熱","originPluginDir":"83647dfda1d31d8e7369fe2d","originPluginID":"83647dfda1d31d8e7369fe2d","parents":{"default_holding_folder_6a8724df01545cc8e3013a":1787245254174},"symbol":"RLAY","updatedAt":1787245254074,"updatedBy":{"agentId":"6cf30c848093a4ccab6df848","agentName":"深度研究員","userId":"6a8724df01545cc8e3013a","userName":"Prean589"},"version":1},{"content":"\u003cp\u003e停經潮熱 NK3R 抗體 ABCL635 為公司主軸，8 月公布 Phase 2 頭對頭數據、成敗一翻兩瞪眼；Vertex 與 Jazz 今年已收 $112M 預付款、現金 $567M+。數據確認前風險偏高，屬高報酬高風險觀察標的。\u003c/p\u003e","createdAt":1787245254074,"id":"815f1f72981a62eb905dcebe","itemType":"RESEARCH_INSIGHT","name":"AbCellera 8 月 ABCL635 頭對頭數據為關鍵二元催化","originPluginDir":"83647dfda1d31d8e7369fe2d","originPluginID":"83647dfda1d31d8e7369fe2d","parents":{"default_holding_folder_6a8724df01545cc8e3013a":1787245254274},"symbol":"ABCL","updatedAt":1787245254074,"updatedBy":{"agentId":"6cf30c848093a4ccab6df848","agentName":"深度研究員","userId":"6a8724df01545cc8e3013a","userName":"Prean589"},"version":1},{"content":"\u003cp\u003eRoche/Genentech 行使第一個 Validated Target Option，證明 AI-native 平台可發現全新生物學；合作已入帳逾 $2.16 億、含最多 40 個小型分子專案。現金 $556.8M 可燒到 2028 初，為 AI 生技主題純度與大廠背書最完整者。\u003c/p\u003e","createdAt":1787245254074,"id":"17d4b612a8394699071f660e","itemType":"RESEARCH_INSIGHT","name":"Recursion 獲 Genentech 行使首個神經科學目標選擇權","originPluginDir":"83647dfda1d31d8e7369fe2d","originPluginID":"83647dfda1d31d8e7369fe2d","parents":{"default_holding_folder_6a8724df01545cc8e3013a":1787245254074},"symbol":"RXRX","updatedAt":1787245254074,"updatedBy":{"agentId":"6cf30c848093a4ccab6df848","agentName":"深度研究員","userId":"6a8724df01545cc8e3013a","userName":"Prean589"},"version":1},{"content":"\u003cp\u003eQ2 營收 68.55 億（年增 90.3%）、毛利率 94.2% 創新高、單季 EPS 6.13 元（年增 204%）；H1 累計 EPS 11.92 元。\u003c/p\u003e","createdAt":1787242841708,"id":"7eff514a762f42c435e59ee2","itemType":"RESEARCH_INSIGHT","name":"Q2 財報亮眼：單季 EPS 6.13 元創新高","originPluginDir":"83647dfda1d31d8e7369fe2d","originPluginID":"83647dfda1d31d8e7369fe2d","parents":{"default_holding_folder_6a8724df01545cc8e3013a":1787242841808},"symbol":"6446","updatedAt":1787242978491,"updatedBy":{"agentId":"ceo","agentName":"CEO","userId":"6a8724df01545cc8e3013a","userName":"Prean589"},"version":2},{"content":"\u003cp\u003e向 TFDA 申請 ET 擴及所有成人、不限治療線別；PV 導入高劑量快速遞增方案。ET 營收占比估由 2026 年 1.6% 升至 2027 年 13.7%。\u003c/p\u003e","createdAt":1787242841708,"id":"dfb10a2a6ff9aa3c26fc5ee6","itemType":"RESEARCH_INSIGHT","name":"ET 適應症擴大與 PV 給藥變更增添成長動能","originPluginDir":"83647dfda1d31d8e7369fe2d","originPluginID":"83647dfda1d31d8e7369fe2d","parents":{"default_holding_folder_6a8724df01545cc8e3013a":1787242841908},"symbol":"6446","updatedAt":1787242978491,"updatedBy":{"agentId":"ceo","agentName":"CEO","userId":"6a8724df01545cc8e3013a","userName":"Prean589"},"version":2},{"content":"\u003cp\u003e法人最高喊買目標價 2,090 元；8/30 美國 ET 藥證 PDUFA 為近期最關鍵催化劑，直接影響評價。\u003c/p\u003e","createdAt":1787242841708,"id":"5692705208bf881055e4d141","itemType":"RESEARCH_INSIGHT","name":"ET 美國藥證 PDUFA 8/30 為近期最關鍵催化劑","originPluginDir":"83647dfda1d31d8e7369fe2d","originPluginID":"83647dfda1d31d8e7369fe2d","parents":{"default_holding_folder_6a8724df01545cc8e3013a":1787242841708},"symbol":"6446","updatedAt":1787242978491,"updatedBy":{"agentId":"ceo","agentName":"CEO","userId":"6a8724df01545cc8e3013a","userName":"Prean589"},"version":2},{"createdAt":1787242791681,"deletedAt":null,"id":"default_holding_folder_6a8724df01545cc8e3013a","isNew":false,"isPublic":false,"itemType":"HOLDING_FOLDER","name":"我的持倉","originPluginDir":"83647dfda1d31d8e7369fe2d","originPluginID":"83647dfda1d31d8e7369fe2d","parents":{"pharma":1787242791681},"preParentID":null,"reviewedAt":0,"updatedAt":1787242791681,"updatedBy":{"userId":"6a8724df01545cc8e3013a","userName":"Prean589"},"version":1},{"avgCost":1288,"createdAt":1787242806638,"displayName":"藥華藥","exchange":"TWSE","id":"45d5b8b61fb8b3efe4d8b125","itemType":"HOLDING","name":"6446 藥華藥","originPluginDir":"83647dfda1d31d8e7369fe2d","originPluginID":"83647dfda1d31d8e7369fe2d","parents":{"default_holding_folder_6a8724df01545cc8e3013a":0},"shares":250,"symbol":"6446","updatedAt":1787242972336,"updatedBy":{"agentId":"ceo","agentName":"CEO","userId":"6a8724df01545cc8e3013a","userName":"Prean589"},"version":3}]}